Iovance Biotherapeutics to Present at Upcoming Investor Conferences in September
August 26 2019 - 4:30PM
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage
biotechnology company developing novel cancer immunotherapies based
on tumor-infiltrating lymphocyte (TIL) technology, today announced
that the company plans to present at the following conferences in
September:
- RW Baird 2019 Global
Healthcare Conference in New York, Sept. 4-5,
2019Location: InterContinental New York BarclayDate/Time:
Wednesday, Sept. 4, at 3:45 p.m. EDT
- Wells Fargo Securities 2019 Healthcare
Conference in Boston, Sept. 4-5, 2019Location: The Westin
Copley PlaceDate/Time: Thursday, Sept. 5, at 8:35 a.m. EDT
- H.C. Wainwright 21st Annual Global Investment
Conference in New York, Sept. 8-10, 2019Location: Lotte
New York PalaceDate/Time: Monday, Sept. 9, at 8:45 a.m. EDT
Live and archived webcasts of the presentations will be
available by visiting the Investors section of the Iovance
Biotherapeutics website at http://ir.iovance.com.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics intends to commercialize autologous cell
therapy products for solid tumors and blood cancers. Tumor
infiltrating lymphocyte (TIL) therapy uses a patient’s own immune
cells to attack cancer cells. TIL are extracted from tumor tissue
and once expanded through a proprietary process are infused back
into the patient. After infusion, TIL enter tumor tissue, where
they recognize, attack, and destroy the tumor. The company is
currently conducting pivotal studies in patients with metastatic
melanoma and advanced cervical cancer. In addition, the company’s
TIL therapies are being investigated for the treatment of patients
with locally advanced, recurrent or metastatic cancers including
head and neck and non-small cell lung cancer. Iovance has also
developed a T cell therapy for blood cancers called peripheral
blood lymphocyte (PBL) therapy and clinical studies in the
treatment of chronic lymphocytic leukemia are being planned. For
more information, please visit www.iovance.com.
Forward-Looking Statements
Certain matters discussed in this press release are
“forward-looking statements” of Iovance Biotherapeutics, Inc.
(hereinafter referred to as the “Company,” “we,” “us,” or “our”).
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. The forward-looking
statements include, but are not limited to, risks and uncertainties
relating to the success, timing, projected enrollment,
manufacturing and production capabilities, and cost of our ongoing
clinical trials and anticipated clinical trials for our current
product candidates (including both Company-sponsored and
collaborator-sponsored trials in both the U.S. and Europe), such as
statements regarding the timing of initiation and completion of
these trials; the timing of and our ability to successfully submit,
obtain and maintain FDA or other regulatory authority approval of,
or other action with respect to, our product candidates, including
those product candidates that have been granted breakthrough
therapy designation (“BTD”) or regenerative medicine advanced
therapy designation (“RMAT”) by the FDA and new product candidates
in both solid tumor and blood cancers; the strength of the
Company’s product pipeline; the successful implementation of the
Company’s research and development programs and collaborations; the
Company’s ability to obtain tax incentives and credits; the
guidance provided for the Company’s future cash, cash equivalent,
and short term investment positions; the success of the Company’s
manufacturing, license or development agreements; the acceptance by
the market of the Company’s product candidates, if approved; and
other factors, including general economic conditions and regulatory
developments, not within the Company’s control. The factors
discussed herein could cause actual results and developments to be
materially different from those expressed in or implied by such
statements. Actual results may differ from those set forth in this
press release due to the risks and uncertainties inherent in the
Company’s business, including, without limitation: the preliminary
clinical results, which may include efficacy and safety results,
from ongoing Phase 2 studies may not be reflected in the final
analyses of these trials; the rate of enrollment may impact the
Company’s clinical trial timelines; enrollment may need to be
adjusted for the Company’s trials and cohorts within those trials
based on FDA and other regulatory agency input; the new version of
the protocol which further defines the patient population to
include more advanced patients in the Company’s cervical cancer
trial may have an adverse effect on the results reported to date;
the data within these trials may not be supportive of product
approval; the Company’s ability to address FDA or other regulatory
authority requirements relating to its clinical programs and
registrational plans, such requirements including, but not limited
to, clinical, safety, manufacturing and control requirements; the
Company’s interpretation of communications with the FDA; risks
related to the Company’s ability to maintain and benefit from
accelerated FDA review designations, including BTD and RMAT, which
may not result in a faster development process or review of the
Company’s product candidates (and which may later be rescinded by
the FDA), and does not assure approval of such product candidates
by the FDA or the ability of the Company to obtain FDA approval in
time to benefit from commercial opportunities; and the ability of
the Company to manufacture its therapies using third party
manufacturers. A further list and description of the Company’s
risks, uncertainties and other factors can be found in the
Company’s most recent Annual Report on Form 10-K and the Company’s
subsequent filings with the Securities and Exchange Commission.
Copies of these filings are available online at www.sec.gov or
www.iovance.com. The forward-looking statements are made only as of
the date of this press release and the Company undertakes no
obligation to publicly update such forward-looking statements to
reflect subsequent events or circumstances.
Investor Relations Contacts: Annie
ChangSolebury Trout646-378-2972achang@troutgroup.com
Chad RubinSolebury Trout646-378-2947crubin@troutgroup.com
Media Relations Contact: Rich AllanSolebury
Trout646-378-2958rallan@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Sep 2023 to Sep 2024